February 7, 2017 12:00 PM
Many of today’s important medications are biological products made from living organisms, manufactured through biotechnology, derived from natural sources, or produced synthetically. Biosimilars are a type of biological product approved by FDA on the basis of being highly similar to an already approved biological reference product, like a generic drug.
This panel of experts will discuss the current state of biosimilars in the healthcare ecosystem and what comes next from a technical and legal perspective. Topics include how the next generation of biosimilars can improve patient access to standard-of-care therapies, the concept of “biobetters,” economic and intellectual property considerations, and policy approaches to support existing and future biosimilars.
- Jennifer DiGiacinto, RRD International
- Robert S. Langer, MIT
- Benjamin Roin, MIT Sloan School of Management
- Moderator: Aaron Kesselheim, Harvard Medical School
This event is free and open to the public. Lunch will be provided.
Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.